GLP-1 Medications and Fertility: Clinical Evidence and Biomark...

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists like semaglutide do not directly enhance fertility, but emerging clinical research suggests weight loss and metabolic improvements associated with these medications may indirectly support reproductive function in patients with obesity-related metabolic dysfunction. Current evidence remains observational, and outcomes vary widely based on individual health factors.

For reproductive-age patients considering GLP-1 therapy, understanding the interplay between metabolic health, body composition, and fertility outcomes is essential. PlexusDx supports precision-guided treatment decisions by helping patients and providers integrate biomarker data and genetic pathway insights before starting compounded GLP-1 medications, ensuring informed conversations aligned with reproductive goals.

How GLP-1 Medications Affect Metabolic Health and Reproductive Function

GLP-1 receptor agonists lower blood glucose, reduce appetite, and promote weight loss—metabolic changes that can improve ovulatory function in women with polycystic ovary syndrome (PCOS) and obesity. Studies show weight loss of 5–10% often restores regular menstrual cycles and improves ovulation rates in affected patients.

However, rapid weight loss itself carries reproductive risks, including potential nutrient deficiencies and hormonal disruption. Reproductive-age patients starting semaglutide or tirzepatide require baseline gynecologic evaluation and monitoring of menstrual regularity, especially if planning pregnancy within 12 months.

Metabolic and Reproductive Factors: A Clinical Decision Framework

Before initiating GLP-1 therapy in reproductive-age patients, providers should assess baseline metabolic health, menstrual patterns, ovulatory status, and pregnancy intentions. This framework helps identify which patients may benefit from GLP-1-induced weight loss versus those requiring alternative approaches or closer monitoring.

Clinical Factor	Relevance to GLP-1 Therapy Decision
PCOS Status	Weight loss via GLP-1 may restore ovulation; baseline assessment essential before treatment
Body Mass Index (BMI)	BMI >30 with metabolic dysfunction may show improved fertility outcomes with structured weight loss
Menstrual Cycle Regularity	Baseline irregular cycles warrant gynecologic evaluation; monitor closely during treatment initiation
Pregnancy Timeline	If pregnancy planned within 6–12 months, discuss GLP-1 timing and potential medication discontinuation with provider
Nutrient Status (Iron, B12, Folate)	Rapid weight loss increases deficiency risk; preconception supplementation recommended before and during therapy

Pregnancy Planning and GLP-1 Medication Continuity

Current clinical guidance recommends discontinuing GLP-1 medications when pregnancy is confirmed, as long-term reproductive safety data remain limited. However, the metabolic improvements achieved during treatment—particularly weight loss and improved insulin sensitivity—may persist and support healthier pregnancy outcomes.

Patients planning to conceive should discuss medication timing, preconception supplementation (folic acid, iron, vitamin D), and monitoring protocols with both their reproductive endocrinologist and primary care provider. Compounded GLP-1 options allow flexible dosing adjustments as pregnancy plans evolve.

Who Should Use Caution and How to Approach Shared Decision-Making

Reproductive-age patients with active infertility, unstable menstrual cycles, or plans to conceive within 6 months require detailed baseline evaluation before starting GLP-1 therapy. Rapid weight loss, medication cost, and adherence logistics should all be discussed in the context of reproductive timeline and goals.

A qualified reproductive health provider should evaluate each patient individually, considering metabolic status, PCOS diagnosis, baseline fertility markers (FSH, AMH, prolactin), and nutritional reserves. PlexusDx genetic and biomarker insights can inform these conversations by clarifying individual predispositions in metabolic and GLP-1 response pathways.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide context about individual predispositions in key metabolic and peptide signaling pathways—including GLP1R, GIPR, FTO, and MC4R variants—that influence weight loss response and metabolic outcomes. These insights should be interpreted with a qualified healthcare provider as part of a comprehensive reproductive and metabolic assessment, not as predictors of fertility outcomes.

Genetic variants associated with GLP-1 receptor sensitivity and fat mass predisposition can inform discussions about treatment suitability and expected metabolic response. For reproductive-age patients, understanding these pathways may help clarify whether GLP-1-induced metabolic improvements are likely to support ovulatory function or whether alternative or complementary approaches should be considered.

Integrating Precision Peptide Genetic Test results with baseline reproductive markers, metabolic labs, and menstrual history can support more informed conversations between patients and providers about GLP-1 therapy timing, expected outcomes, and alignment with fertility goals. This precision-guided approach reduces trial-and-error treatment decisions and supports reproductive autonomy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.